UAE Business: Bioventure Healthcare to expand production – Gulf Digital News

UAE Business: Bioventure Healthcare to expand production – Gulf Digital News

The newly rebranded Bioventure Healthcare plans to expand the production capacity of its manufacturing plant by introducing new products such as oral solid tablets, capsules and sachets lines by 2023.

A strategic partner of multinational companies and a key exporter to the US, Bioventure’s expansion will lead to an increase in the firm’s market share in the therapeutic categories of antihypertensive, anti-diabetes, anti-hypercholesterolemia, cardiovascular (CV), gastroenterology, gastrointestinal (GIT) health, immunity, men and women’s health products, and other critical speciality products.

It also plans to add more unique dosage forms to increase the range of delivery systems, with the aim of catering to the growing pharmaceutical needs of the UAE and the wider region.

Rebranding announced

The expansion plans come soon after GlobalOne Healthcare Holding (GHH), Yas Holding’s Healthcare Division, announced the rebranding of its subsidiary Geltec Healthcare as Bioventure Healthcare.

This is part of its strategy to strengthen its business and drive growth in the pharmaceutical and supplement manufacturing industry.

The rebranding is aligned with GlobalOne Healthcare’s commitment to delivering healthcare outcomes and patient quality of life, as well as the UAE Government’s ‘Operation 300bn’.

Developing the Pharma sector

An initiative that aims to develop the country’s industrial sector and enhance its role in stimulating the national economy,